Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)

(Stock Code: 01099)

ANNOUNCEMENT

PRINCIPAL FINANCIAL DATA OF CNMDC

FOR THE THREE MONTHS ENDED 31 MARCH 2021

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

Reference is made to the overseas regulatory announcement dated 26 April 2021 (the "Announcement") issued by Sinopharm Group Co. Ltd. (the "Company") in relation to the unaudited consolidated balance sheet, income statement and cash flow statement, and the unaudited balance sheet, income statement and cash flow statement of China National Medical Device Co., Ltd. (中國醫療器械有限公司)("CNMDC"), a subsidiary of the Company for the three months ended 31 March 2021 (the "Reporting Period") issued by CNMDC on the websites of China Money and Shanghai Clearing House.

The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal unaudited financial data of CNMDC for the three months ended 31 March 2021 as set out in the Announcement.

1

PRINCIPAL FINANCIAL DATA OF THE CONSOLIDATED FINANCIAL STATEMENTS

Unit: Yuan

Currency: RMB

Changes of this The Reporting Period Same period of last year period over the same period of last year

Revenue Operating profit

Total comprehensive income attributable to owners of the parent company

Net cash flow arising from operating activities

Total assets

Total equity attributable to owners of the parent company

14,111,844,359.67

501,446,953.21

213,890,050.95

-4,696,462,346.88

At the end of the Reporting Period

39,832,920,930.22

5,561,172,130.24

9,239,323,674.16

52.74%

345,879,603.08

44.98%

130,532,220.39

63.86%

-3,654,837,058.60

28.50%

Changes of this

At the beginning of the

period-end over the

Reporting Period

beginning of this

period

38,228,498,838.96

4.20%

5,347,282,079.29

4.00%

By order of the Board

Sinopharm Group Co. Ltd.

Yu Qingming

Chairman

Shanghai, the PRC

26 April 2021

As at the date of this announcement, the executive directors of the Company are Mr. Yu Qingming and Mr. Liu Yong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Ma Ping, Mr. Hu Jianwei, Mr. Deng Jindong, Mr. Wen Deyong, Ms. Guan Xiaohui and Ms. Feng Rongli; and the independent non-executive directors of the Company are Mr. Zhuo Fumin, Mr. Chen Fangruo, Mr. Li Peiyu, Mr. Wu Tak Lung and Mr. Yu Weifeng.

  • The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name "Sinopharm Group Co. Ltd.".

2

Attachments

  • Original document
  • Permalink

Disclaimer

Sinopharm Group Co. Ltd. published this content on 26 April 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 April 2021 11:16:04 UTC.